Introduction: Since June 2005, the University Hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR) has been an International Committee of Medical Journal Editors (ICMJE)-approved clinical trial registry in Japan. The number of clinical trials registered in the UMIN-CTR has increased annually. To date, no report exists regarding the publishing of clinical trials registered in the UMIN-CTR. Therefore, we evaluated the publication frequency of clinical trials registered in the UMIN-CTR in Japan. Methods: We targeted trials that assessed the treatment effect of chemotherapy or molecular targeting drugs for lung cancer. We included trials registered between June 2005 and January 2010, and identified published trials through a computer-based search of MEDLINE and Google Scholar. The cumulative publication rate of the trials was calculated using Kaplan-Meier analysis. Results: In our study, 179 trials met the inclusion criteria. Of these, 46.4% (83/179) trials were published by the end of the cut-off period. With regard to publication, differences existed between the information recorded in the UMIN-CTR database and the actual searched results. The publication rate between groups was insignificantly different; however, whether a clinical study group did or did not conduct a trial differed significantly (53.3% vs. 36.1%; P = 0.024). Phase II studies with positive results were more likely to be published (84.4%); however, the overall publication rate was low (41.8%), which may reflect publication bias. Conclusions: The UMIN-CTR fundamentally functions as the unique ICMJE-approved clinical trial registry in Japan. However, it seems insufficient to require it as the official clinical database.
Introduction
ClinicalTrials.gov is the largest clinical trial registry maintained by the United States National Library of Medicine at the National Institutes of Health (NIH; Bethesda, MD, USA), which has registered more than 250 000 trials from 200 countries in the world (1) . In 2005, the International Committee of Medical Journal Editors (ICMJE) began to require registering prospective trials involving human participants before beginning the study as a prerequisite for publication in its member journals (2) . The 2007 United States Food and Drug Administration (FDA) Amendments Act required sponsors of the trials of FDA-regulated products to register the information of the trials before initiating the trial and the results of the trial on the ClinicalTrials.gov database (3, 4) . If the investigators fail to comply with this requirement, they receive substantial penalties such as civil fines of up to $10 000 per day and the NIH suspends its funding of the trial (4) .
In response to the global movement for clinical trial registration, the University Hospital Medical Information Network (UMIN) established the first clinical trial registry, UMIN-Clinical Trial Registry (UMIN-CTR), in Japan in June 2005; it was an ICMJEapproved clinical trial registration site (5) . The number of clinical trials registered in the UMIN-CTR has increased annually. As of August 2017, more than 28 000 clinical trials have been registered in the UMIN-CTR. The consensus that clinical trials should be registered in advance has been generally accepted in Japan, although there are no strict laws that researchers should update the information on UMIN-CTRs or publish the results of each trial. Strict laws exist with respect to the replacement of information recorded on the database in the USA; however, Jones et al. (6) and other investigators (7) reported a low frequency of the results of clinical trials registered with ClinicalTrials.gov and limited availability of results in the ClinicalTrials.gov database. Moreover, trials primarily sponsored by industry were more likely to be published, compared with trials sponsored by the NIH or other federal sources (6, 8) . Furthermore, studies that have 'positive' results (including any 'significant' results) are published more often than studies with 'negative' results (9) (10) (11) .
In general, publication bias makes it difficult to interpret the results of a meta-analysis and leads to the overestimation of treatment effects (12) . To date, there is no report regarding the publication of clinical trials registered with the UMIN-CTR. Therefore, we evaluated the frequency of unpublished clinical trials registered with the UMIN-CTR in Japan.
Materials and methods

The UMIN-CTR query
The UMIN-CTR is the main clinical trial registry in Japan with more than 28 000 clinical trials registered, as of August 2017. The information of the individual trials is recorded and includes background details, condition, objectives, assessment, intervention, study design, eligibility, recruitment participant number, funding source, progress status, etc. The primary investigators or sponsors received an e-mail from the UMIN-CTR that encouraged them to update the information. Every 6 months, the information-especially the trial progress status-needed to be updated.
The progress status is listed as one of the following: 'Preinitiation', indicating that the trial will soon start enrollment; 'Open public recruiting' or 'Enrollment by invitation', indicating an ongoing study for which participants are recruited publicly or by invitation, respectively; 'Suspended', indicating that the trial had started to enroll participants but suspended the enrollment for some reason, although the trial is considered as ongoing; 'No longer recruiting', indicating that participants were no longer being enrolled but the study is considered as ongoing; 'Main results already published' or 'Terminated', indicating that the study started the enrollment process but was stopped early for some reason; or 'Completed', indicating that the trial ended normally.
We included trials that were registered from 1 June 2005, which was when the UMIN-CTR was established, to 1 January 2010. The main objective of the included trials was to assess the treatment effect of chemotherapy or molecular targeting drugs on lung cancer. We excluded trials that were registered after 1 January 2010 because of the possibility that the publication of the trial was delayed because the study was not completed; trials that targeted cancers other than lung cancer or multiple cancers (including lung cancer); trials in which the main objective was to assess novel diagnostic methods; epidemiological studies; and studies that focused on the development of biomarkers or evaluated other drugs. We also excluded duplicate registry entries of a trial.
We conducted a search for trials reported at the time of 30 October 2014. We identified published trials through a computerbased search of the MEDLINE database and the Google Scholar database. We searched the following information, as recorded in the UMIN-CTR: UMIN-CTR IDs, investigator's name, trial title, methods, study design, clinical study group or organization responsible for the study, and specific clinical study number in the organization. To avoid bias in the data abstraction process, four medical oncologists (NO, YH, HY and NT)-two of whom (NO and NT) hold board certification in medical oncology-abstracted the data independently from the trials and subsequently compared the results, as described previously (13, 14) .
The following information was obtained from each report: date of publication, number of patients enrolled, proportion of patients with a good performance status, proportion of male patients, median age of patients and whether the study did or did not meet the primary endpoint.
Definition of 'positive' or 'negative' in each study
We defined a 'positive study' as one that met the primary endpoint described in the article. We identified some publications in which, although the study did not meet the primary endpoint, the investigators concluded that the results appeared to be 'positive' because of less toxicity, better quality of life, or for other reasons. However, we defined these trials as 'negative' in this study.
Statistical analyses
We used chi-squared tests to compare publication rates between trials, based on characteristics such as histology, number of participants, trial design, and clinical trial group or organization responsible for the study. We used the Kaplan-Meier method to estimate the cumulative publication rate over time after the trial initiation. All unpublished studies were censored on the date of the final manuscript search. All P-values corresponded to two-sided tests, and significance was set at P < 0.05. Statistical analyses were conducted using STATA software (ver. 14; StataCorp, College Station, TX, USA).
Results
Trial flow and characteristics of the trials Figure 1 shows the flow chart of this study. We identified 5867 trials, based on our initial computer-based search. Of these trials, we excluded 4645 trials that were registered after 1 January 2010. Of the remaining 1222 clinical trials, we excluded the trials that targeted cancers other than lung cancer or that targeted multiple cancers, including lung cancer. In 203 trials for lung cancer, we excluded trials regarding diagnosis (n = 13), epidemiological study (n = 2), development of biomarker (n = 3) and evaluation for the drug used for treatment (n = 6). Finally, 179 eligible trials were identified as a result of screening.
The number of the trials registered with the UMIN-CTR has increased three-fold in 5 years (Supplementary Figure 1A) . By contrast, the median number of preplanned participants in the trials per year, plotted by the year of protocol approval, has significantly decreased (Supplementary Figure 1B) . The major primary sites targeted in the trials were lung (16.6%), colon (11.3%), hematopoietic (11.0%), gastric (9.9%), breast (8.8%) and liver (5.0%) (Supplementary Table 1) . Table 1 lists the characteristics of the eligible 179 trials. Of these trials, 150 (83.8%) trials evaluated the treatment of non-small cell lung cancer (NSCLC), 24 (13.4%) trials evaluated small cell lung cancer (SCLC), and five (2.8%) trials evaluated the histology of both. Approximately two-thirds (61.5%) of the eligible trials were conducted using a Phase II design, and 32 (17.9%) trials were conducted using a Phase III design. The number of trials that were initially planned to have 100 or more participants or to have less than 100 participants were 46 (25.7%) and 133 (74.3%), respectively. Most (71.5%) of the eligible trials were reported as 'Self funding.' As shown in Table 1 , more than 50% of these trials would have been planned to be ended within 48 months.
Publication rate of all eligible trials and the association between trial characteristics and the publication of the trial
Overall, 179 trials met the inclusion criteria in our study. We finally identified 83 (46.4%) of 179 trials as published manuscripts ( Fig. 2A) . Figure 2B shows a summary of the information regarding the publication status, as recorded with the UMIN-CTR. The inconsistency between these results suggested that the information of the UMIN-CTR may not have been adequately updated. Table 2 shows the publication rate stratified by characteristics. There were no significant differences in the publication rate between histology, planned number of participants and trial design; however, trials conducted by a study group were published significantly more often than trials conducted by a single institution (53.3% vs. 36.1%; P = 0.024).
Association between study outcome and the publication of the trials Figure 3 shows the proportion of studies with positive results by study setting. The findings suggested that studies with negative results were more likely to be published in Phase III settings. By contrast, most (84.4%) published Phase II studies reported positive results. Based on the low publication rate of Phase II studies (41.8%), as seen in Table 2 , we surmised that there were a few studies with negative results among the remaining unpublished studies.
Cumulative publication rate of the trials from trial initiation
Supplementary Figure 2A shows the Kaplan-Meier curve for the time to publication of a study from the time of trial initiation. The median time to publication was 100 months (95% confidence interval, 84-125). The period from trial registration with the UMIN-CTR to the last update of the information is summarized in Table 3 . It was surprising that only 39 (21.8%) of 179 studies were updated in less than 24 months. We divided the trials into two groups, based on the period. The studies with a period of less than 24 months tended to be published less often (Supplementary Figure 2B ; P = 0.0683, log-rank test). The difference between groups was evaluated using the chi-square test. A P-value <0.05 is significant. 
Discussion
In this study, we found that the overall publication rate was 46.4% and the publication rate of Phase II trials and Phase III trials were 41.8% and 50.0%, respectively. There were no significant differences in the publication rate between trial settings. However, the percentage of the trials with positive results was significantly higher than that of the trials with negative results (P < 0.0001). Studies with 'positive' results (including any 'significant' results) were published more often than studies with 'negative' results (9-11,15-17). Scherer et al. reported reasons authors did not publish their trial results in full after they presented their findings as abstracts at biomedical conferences: 'lack of time' was the main reason authors did not subsequently publish, followed by 'lack of time and/or resources,' 'publication was not an aim,' 'low priority,' and 'trouble with coauthors' (18). Jones et al. reported that the overall publication rate of large randomized trials involving 500 patients or more was 71.0% (414/585); these trials were registered with ClinicalTrials.gov before 1 January 2009. Jones also noted that the nonpublication rate was significantly low in trials supported by the NIH or other federal funding sources, compared with the rate of trials without federal funding (17% vs. 31%, P = 0.025) (6). Ross et al. also reported that trials primarily sponsored by industry were significantly less likely to be published, compared with studies sponsored by nongovernment or non-industry sources (40% vs. 56%, P < 0.001). However, there was no significant difference in publication rates between industry-funded trials and government-funded trials (40% vs. 47%, P = 0.22) (7). Ross also reported differences in publication rates among industry sponsors with ten or more trials, which varied widely from 26 to 93%.
In our study, we did not analyze the relationship between publication and the funding source. With regard to the funding source, most (71.5%; 128/179) eligible trials were recorded as being 'selffunded' and 17.9% (32/179) of the remaining trials were recorded as having 'federal funding.' Only 4.5% (8/179) of trials were recorded as having 'industry funding.' We searched for the trials registered with ClinicalTrials.gov under the same condition in our study and we finally identified 39 eligible trials. Of them, 59.0% (23/39) were reported as having 'industry funding.' The proportion of trials with 'industry funding' identified in this study seemed so low that we could not exclude the possibility that the funding source data was incorrectly reported. Further exploration is warranted to clarify the essential factors that contributed to this trend.
It may be unrealistic to expect that all trials should be published, regardless of the situation. If the investigators or the trial sponsor would experience financial risk because of the publication of negative results, then the publication may be delayed or suppressed. Furthermore, as Scherer et al. reported, several authors considered 'publication not an aim' for their clinical trials results in the first place (18) . If so, their aim was achieved so that they could make a presentation at medical conferences.
Our study has several limitations. First, because of the lack of up-to-date information by the investigators, we could not identify whether the trial was completed. Therefore, we had no alternative but to adopt a trial initiation date or a trial registration date instead of trial completion date. Trials for which the study's end date was described were more likely to be published, compared with trials lacking this information (51% vs. 40%, P = 0.005) (7) . Second, we considered a 'positive study' simply as a study that had met the To examine whether the publication of these trials were complete, we searched the MEDLINE and the Google Scholar database in October 2014. Databases other than these two and/or publications after October 2014 were not analyzed in this study. More search engine databases and longer follow up may be necessary in future investigations.
In conclusion, the UMIN-CTR fundamentally functions as a unique ICMJE-approved clinical trial registry in Japan; however, it seems to be insufficient as to whether it can function fully to be required as the official clinical database. Above all, researchers and investigators should keep in mind that a substantial number of study participants did not contribute to the social benefits of the findings of the trials because the trial results were unpublished, and should seriously consider what needs to be done as unbiased researchers.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online.
